- Home
- SAVA vs DCOM Comparison
SAVA vs DCOM Comparison
Compare SAVA & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- DCOM
- Stock Information
- Founded
- SAVA 1998
- DCOM 1864
- Country
- SAVA United States
- DCOM United States
- Employees
- SAVA N/A
- DCOM N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- DCOM Major Banks
- Sector
- SAVA Health Care
- DCOM Finance
- Exchange
- SAVA Nasdaq
- DCOM Nasdaq
- Market Cap
- SAVA 1.3B
- DCOM 1.2B
- IPO Year
- SAVA N/A
- DCOM 1996
- Fundamental
- Price
- SAVA $29.58
- DCOM $31.45
- Analyst Decision
- SAVA Strong Buy
- DCOM Strong Buy
- Analyst Count
- SAVA 3
- DCOM 5
- Target Price
- SAVA $111.50
- DCOM $29.60
- AVG Volume (30 Days)
- SAVA 2.2M
- DCOM 185.6K
- Earning Date
- SAVA 11-05-2024
- DCOM 10-22-2024
- Dividend Yield
- SAVA N/A
- DCOM 3.27%
- EPS Growth
- SAVA N/A
- DCOM N/A
- EPS
- SAVA N/A
- DCOM 1.55
- Revenue
- SAVA N/A
- DCOM $320,386,000.00
- Revenue This Year
- SAVA N/A
- DCOM N/A
- Revenue Next Year
- SAVA N/A
- DCOM $21.24
- P/E Ratio
- SAVA N/A
- DCOM $20.32
- Revenue Growth
- SAVA N/A
- DCOM N/A
- 52 Week Low
- SAVA $8.79
- DCOM $17.29
- 52 Week High
- SAVA $42.20
- DCOM $31.75
- Technical
- Relative Strength Index (RSI)
- SAVA 57.03
- DCOM 74.17
- Support Level
- SAVA $24.13
- DCOM $27.32
- Resistance Level
- SAVA $31.23
- DCOM $31.75
- Average True Range (ATR)
- SAVA 2.16
- DCOM 0.92
- MACD
- SAVA 0.20
- DCOM 0.25
- Stochastic Oscillator
- SAVA 72.41
- DCOM 93.32
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
About DCOM Dime Community Bancshares Inc.
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities.